Cargando…

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

BACKGROUND: The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study, we investigated the prognostic utilities and most suitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurozumi, Sasagu, Matsumoto, Hiroshi, Hayashi, Yuji, Tozuka, Katsunori, Inoue, Kenichi, Horiguchi, Jun, Takeyoshi, Izumi, Oyama, Tetsunari, Kurosumi, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441075/
https://www.ncbi.nlm.nih.gov/pubmed/28532429
http://dx.doi.org/10.1186/s12885-017-3331-4
_version_ 1783238191205056512
author Kurozumi, Sasagu
Matsumoto, Hiroshi
Hayashi, Yuji
Tozuka, Katsunori
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Kurosumi, Masafumi
author_facet Kurozumi, Sasagu
Matsumoto, Hiroshi
Hayashi, Yuji
Tozuka, Katsunori
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Kurosumi, Masafumi
author_sort Kurozumi, Sasagu
collection PubMed
description BACKGROUND: The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study, we investigated the prognostic utilities and most suitable cut-off values for Ki67 and PgR, and evaluated the relationship between Ki67 LI and PgR expression in ER-positive/HER2-negative breast cancer. PATIENTS AND METHODS: In the present study, 177 consecutive Japanese women with ER-positive/HER2-negative invasive carcinoma of no special type who were treated between 2000 and 2001 were enrolled. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed according to Ki67 LI and PgR expression, and significant cut-off values for selecting patients with a poor prognosis were evaluated. RESULTS: The cut-off values for Ki67 LI as a prognostic marker plotted against P values showed bimodal peaks at 10% and 30%. Among the cut-off points examined for the PgR status, 20% PgR positivity was the most significant for predicting survival differences (RFS: P = 0.0003; CSS: P < 0.0001). A multivariate analysis showed that PgR (≥20%) was an independent prognostic marker (RFS: P = 0.0092; CSS: P = 0.00014). Furthermore, in the intermediate risk group with Ki67 LI of 10–30%, the low PgR <20% group had a markedly poorer prognosis for RFS and CSS (RFS: P < 0.0001; CSS: P < 0.0001). CONCLUSIONS: The expression of PgR is a potent prognostic indicator for evaluating the long-term prognosis of ER-positive/HER2-negative breast cancer, and the most suitable cut-off value was found to be 20%. Furthermore, the PgR status is a powerful method for selecting patients with a poor prognosis among ER-positive/HER2-negative patients at intermediate risk, as assessed using Ki67 LI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3331-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5441075
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54410752017-05-24 Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index Kurozumi, Sasagu Matsumoto, Hiroshi Hayashi, Yuji Tozuka, Katsunori Inoue, Kenichi Horiguchi, Jun Takeyoshi, Izumi Oyama, Tetsunari Kurosumi, Masafumi BMC Cancer Research Article BACKGROUND: The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study, we investigated the prognostic utilities and most suitable cut-off values for Ki67 and PgR, and evaluated the relationship between Ki67 LI and PgR expression in ER-positive/HER2-negative breast cancer. PATIENTS AND METHODS: In the present study, 177 consecutive Japanese women with ER-positive/HER2-negative invasive carcinoma of no special type who were treated between 2000 and 2001 were enrolled. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed according to Ki67 LI and PgR expression, and significant cut-off values for selecting patients with a poor prognosis were evaluated. RESULTS: The cut-off values for Ki67 LI as a prognostic marker plotted against P values showed bimodal peaks at 10% and 30%. Among the cut-off points examined for the PgR status, 20% PgR positivity was the most significant for predicting survival differences (RFS: P = 0.0003; CSS: P < 0.0001). A multivariate analysis showed that PgR (≥20%) was an independent prognostic marker (RFS: P = 0.0092; CSS: P = 0.00014). Furthermore, in the intermediate risk group with Ki67 LI of 10–30%, the low PgR <20% group had a markedly poorer prognosis for RFS and CSS (RFS: P < 0.0001; CSS: P < 0.0001). CONCLUSIONS: The expression of PgR is a potent prognostic indicator for evaluating the long-term prognosis of ER-positive/HER2-negative breast cancer, and the most suitable cut-off value was found to be 20%. Furthermore, the PgR status is a powerful method for selecting patients with a poor prognosis among ER-positive/HER2-negative patients at intermediate risk, as assessed using Ki67 LI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3331-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-22 /pmc/articles/PMC5441075/ /pubmed/28532429 http://dx.doi.org/10.1186/s12885-017-3331-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kurozumi, Sasagu
Matsumoto, Hiroshi
Hayashi, Yuji
Tozuka, Katsunori
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Kurosumi, Masafumi
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
title Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
title_full Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
title_fullStr Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
title_full_unstemmed Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
title_short Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
title_sort power of pgr expression as a prognostic factor for er-positive/her2-negative breast cancer patients at intermediate risk classified by the ki67 labeling index
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441075/
https://www.ncbi.nlm.nih.gov/pubmed/28532429
http://dx.doi.org/10.1186/s12885-017-3331-4
work_keys_str_mv AT kurozumisasagu powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT matsumotohiroshi powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT hayashiyuji powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT tozukakatsunori powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT inouekenichi powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT horiguchijun powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT takeyoshiizumi powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT oyamatetsunari powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex
AT kurosumimasafumi powerofpgrexpressionasaprognosticfactorforerpositiveher2negativebreastcancerpatientsatintermediateriskclassifiedbytheki67labelingindex